Description of Research: Krishna Rao
Dr. Rao’s clinical and research interests include the diagnosis and management of healthcare-associated infections, especially Clostridium difficile infection. His clinical work includes managing the University of Michigan Fecal Microbiota Transplantation (stool transplant) program for recurrent Clostridium difficile infection, which he co-founded. He also works with the Antimicrobial Subcommittee of the Pharmacy and Therapeutics Committee, where he provides expertise and support in the use of procalcitonin, a novel and promising biomarker for bacterial infections. He studies infections in older adults and the biology of aging, in affiliation with the Claude D. Pepper Older Americans Independence Center of the University of Michigan Institute of Gerontology and the Patient Safety Enhancement Program.
His research is primarily conducted through the Enterics Research Investigative Network. His overall research aim is to investigate how biochemical, microbiological, and clinical factors can help decision-making in the treatment of healthcare-associated infections, and he hopes ultimately to integrate these factors into robust risk-prediction algorithms for use by clinicians.
Rao K, Walk ST, Micic D, Chenoweth E, Deng L, Galecki AT, Jain R, Trivedi I, Yu M, Santhosh K, Ring C, Young VB, Huffnagle GB, Aronoff DM. Procalcitonin Levels Associate with Severity of Clostridium difficile Infection. PLoS One. 2013;8(3):e58265. PMCID: 3591407.
Rao K, Berland D, Young C, Walk ST, Newton DW. The Nose Knows Not: Poor Predictive Value of Stool Sample Odor for Detection of Clostridium difficile. Clin Infect Dis. 2013;56(4):615-6. PMCID: 3571629.
Bagdasarian N, Rao K, Malani P. Changing Epidemiology and Control of Clostridium difficile in Older Adults. Curr Transl Geriatr and Exp Gerontol Rep. 2013;2(3):143-50. DOI: 10.1007/s13670-013-0049-2.
Rao K, Micic D, Chenoweth E, Deng L, Galecki AT, Ring C, Young VB, Aronoff DM, Malani PN. Poor Functional Status as a Risk Factor for Severe Clostridium difficile Infection in Hospitalized Older Adults. J Am Geriatr Soc. 2013;61(10):1738-42. PMCID: 3801297.
Rao K, Young VB, Aronoff DM. Commentary: Fecal Microbiota Therapy: Ready for Prime Time? Infect Control Hosp Epidemiol. 2014;35(1):28-30. DOI: 10.1086/674395.
Rao K, Erb-Downward JR, Walk ST, Micic D, Falkowski N, Santhosh K, Mogle JA, Ring C, Young VB, Huffnagle GB, Aronoff DM. The Systemic Inflammatory Response to Clostridium difficile Infection. PLoS ONE. 2014;9(3):e92578. PMCID: 3958555
Islam J, Taylor AL, Rao K, Huffnagle G, Young VB, Rajkumar C, Cohen J, Papatheodorou P, Aronoff DM, Llewelyn MJ. The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: A case–control study. Anaerobe. 2014;27(0):82-6.
Corsello PM, Micic D, Rao K, Waljee AK. Challenges in the diagnosis of Clostridium difficile Infection. Gastroenterol. 2014.
Kelly C, Ihunnah C, Fischer M, Khoruts A, Brandt L, Afzali A, Aroniadis O, Barto A, Borody T, Giovanelli A, Gordon S, Gluck M, Hohmann E, Kao D, Kao JY, McQuillen D, Mellow M, Rank K, Rao K, Ray A, Schwartz M, Singh N, Stollman N, Surawicz C, Suskind D, Vindgni S, Youngster I. Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients. Am J Gastroenterol. 2014;in press.